Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences between clinical trial efficacy and real-world effectiveness.

Michael H Davidson1

  • 1Rush University Medical Center, 1725 W Harrison St, Ste 1159, Chicago, IL 60612, USA. michaeldavidson@radiantresearch.com

The American Journal of Managed Care
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

The emerging role of CETP inhibition in the prevention of Alzheimer's disease.

American journal of preventive cardiology·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026

Aggressive statin therapy effectively lowers low-density lipoprotein cholesterol (LDL-C), reducing coronary heart disease (CHD) risks. High-efficacy LDL-C lowering enhances achievement of NCEP ATP III guidelines in real-world settings.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Coronary heart disease (CHD) morbidity and mortality are reduced by aggressive low-density lipoprotein cholesterol (LDL-C) lowering with statin therapy.
  • Real-world studies (L-TAP, NEPTUNE II) show many patients do not achieve NCEP ATP III LDL-C goals.
  • Therapeutic gaps exist due to factors like poor follow-up, suboptimal statin choice, adherence issues, cost, and patient motivation.

Purpose of the Study:

  • To review evidence supporting aggressive statin therapy for achieving LDL-C goals.
  • To highlight the effectiveness of high-efficacy statins in real-world clinical practice.
  • To address the treatment gap in LDL-C management.

Main Methods:

  • Review of large clinical trials conducted since NCEP ATP III.

Related Experiment Videos

  • Analysis of data from real-world clinical settings.
  • Evaluation of statin therapy efficacy in achieving LDL-C targets.

    • Main Results:

    • Aggressive statin therapy has been shown in clinical trials to be effective in achieving LDL-C goals.
    • High-efficacy LDL-C lowering therapy enhances the achievement of NCEP ATP III guidelines.
    • These goals are achievable outside of controlled trial settings.

    Conclusions:

    • Starting or switching to high-efficacy statin therapy improves LDL-C control.
    • Aggressive LDL-C lowering is crucial for reducing CHD events in primary and secondary prevention.
    • Addressing therapeutic gaps with effective statin strategies is essential for patient outcomes.